RT Journal Article
SR Electronic
T1 “Clinical characteristics, symptoms, management and health outcomes in 8,598 pregnant women diagnosed with COVID-19 compared to 27,510 with seasonal influenza in France, Spain and the US: a network cohort analysis”
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.13.20211821
DO 10.1101/2020.10.13.20211821
A1 Lai, Lana Yin Hui
A1 Golozar, Asieh
A1 Sena, Anthony
A1 Margulis, Andrea V.
A1 Haro, Nuria
A1 Casajust, Paula
A1 Valveny, Neus
A1 Prats-Uribe, Albert
A1 Minty, Evan P.
A1 Ahmed, Waheed-Ul-Rahman
A1 Alshammari, Thamir M
A1 Morales, Daniel R.
A1 Alghoul, Heba
A1 Alser, Osaid
A1 Dawoud, Dalia
A1 Zhang, Lin
A1 Posada, Jose D.
A1 Shah, Nigam H.
A1 Blacketer, Clair
A1 Areia, Carlos
A1 Subbian, Vignesh
A1 Nyberg, Fredrik
A1 Lane, Jennifer C E
A1 Suchard, Marc A
A1 Gong, Mengchun
A1 Recalde, Martina
A1 Jonnagaddala, Jitendra
A1 Shah, Karishma
A1 Roel, Elena
A1 Vizcaya, David
A1 Fortin, Stephen
A1 Joanne Cheng, Ru-fong
A1 Reich, Christian
A1 Hripcsak, George
A1 Rijnbeek, Peter
A1 Ryan, Patrick
A1 Kostka, Kristin
A1 Duarte-Salles, Talita
A1 Prieto-Alhambra, Daniel
YR 2020
UL http://medrxiv.org/content/early/2020/10/14/2020.10.13.20211821.abstract
AB OBJECTIVES To describe comorbidities, symptoms at presentation, medication use, and 30-day outcomes after a diagnosis of COVID-19 in pregnant women, in comparison to pregnant women with influenza.DESIGN Multinational network cohortSETTING A total of 6 databases consisting of electronic medical records and claims data from France, Spain, and the United States.PARTICIPANTS Pregnant women with ≥ 1 year in contributing databases, diagnosed and/or tested positive, or hospitalized with COVID-19. The influenza cohort was derived from the 2017-2018 influenza season.OUTCOMES Baseline patient characteristics, comorbidities and presenting symptoms; 30-day inpatient drug utilization, maternal complications and pregnancy-related outcomes following diagnosis/hospitalization.RESULTS 8,598 women diagnosed (2,031 hospitalized) with COVID-19 were included. Hospitalized women had, compared to those diagnosed, a higher prevalence sof pre-existing comorbidities including renal impairment (2.2% diagnosed vs 5.1% hospitalized) and anemia (15.5% diagnosed vs 21.3% hospitalized).The ten most common inpatient treatments were systemic corticosteroids (29.6%), enoxaparin (24.0%), immunoglobulins (21.4%), famotidine (20.9%), azithromycin (18.1%), heparin (15.8%), ceftriaxone (7.9%), aspirin (7.0%), hydroxychloroquine (5.4%) and amoxicillin (3.5%).Compared to 27,510 women with influenza, dyspnea and anosmia were more prevalent in those with COVID-19. Women with COVID-19 had higher frequency of cesarean-section (4.4% vs 3.1%), preterm delivery (0.9% vs 0.5%), and poorer maternal outcomes: pneumonia (12.0% vs 2.7%), ARDS (4.0% vs 0.3%) and sepsis (2.1% vs 0.7%). COVID-19 fatality was negligible (N<5 in each database respectively).CONCLUSIONS Comorbidities that were more prevalent with COVID-19 hospitalization (compared to COVID-19 diagnosed) in pregnancy included renal impairment and anemia. Multiple medications were used to treat pregnant women hospitalized with COVID-19, some with little evidence of benefit. Anosmia and dyspnea were indicative symptoms of COVID-19 in pregnancy compared to influenza, and may aid differential diagnosis. Despite low fatality, pregnancy and maternal outcomes were worse in COVID-19 than influenza.WHAT IS ALREADY KNOWN ON THIS TOPICCompared to non-pregnant women of reproductive age, pregnant women are less likely to experience typical COVID-19 symptoms, such as fever and myalgia.Obesity, high maternal age, and comorbid hypertension and diabetes are risk factors for severe COVID-19 among pregnant women.Despite relatively high rates of pneumonia and need for oxygen supplementation, fatality rates in pregnant women with COVID-19 are generally low (<1%).WHAT THIS STUDY ADDSAlthough not often recorded, dyspnea and anosmia were more often seen in pregnant women with COVID-19 than in women with seasonal influenza, in 6 databases from 3 countries (US, France, Spain).Renal impairment and anemia were more common among hospitalized than diagnosed women with COVID-19 during pregnancy.Despite limited data on benefit-risk in pregnancy, a large number of medications were used for inpatient management of COVID-19 in pregnant women: approximately 1 in 3 received corticosteroids (some may have been given for a pregnancy-related indication rather than for COVID-19 treatment), 1 in 4 enoxaparin, and 1 in 5 immunoglobulin, famotidine and azithromycin.Compared to influenza, there was a higher frequency of pregnancy-related complications (cesarean section and preterm deliveries), as well as poorer maternal outcomes (pneumonia, acute respiratory distress syndrome, sepsis, acute kidney injury, and cardiovascular and thromboembolic events) seen in pregnant women diagnosed with COVID-19.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: AG reports personal fees from Regeneron Pharmaceuticals, outside the submitted work; and she a full-time employee at Regeneron Pharmaceuticals. KK and CR report being employees of IQVIA. RJC reports being an employee of Johnson & Johnson. FN was an employee of AstraZeneca until 2019 and holds AstraZeneca shares. AVM is a full-time employee of RTI Health Solutions; RTI Health Solutions is a unit of RTI International, an independent, nonprofit organization that conducts work for government, public and private organizations, including pharmaceutical companies. The views expressed are those of the authors and do not necessarily represent the views or policy of the United States Government. DRM is supported by a Wellcome Trust Clinical Research Development Fellowship (Grant 214588/Z/18/Z). No other relationships or activities that could appear to have influenced the submitted work.Funding StatementThe European Health Data & Evidence Network has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Unions Horizon 2020 research and innovation programme and EFPIA. This research received partial support from the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), US National Institutes of Health, US Department of Veterans Affairs, Janssen Research & Development, and IQVIA. The University of Oxford received funding related to this work from the Bill & Melinda Gates Foundation (Investment ID INV-016201 and INV-019257). The IDIAPJGol received funding from the Health Department from the Generalitat de Catalunya with a grant for research projects on SARS-CoV-2 and COVID-19 disease organized by the Direccio General de Recerca i Innovacio en Salut. DPA received funding from the NIHR Academy in the form of an NIHR Senior Research Fellowship. WURA reports funding from the NIHR Oxford Biomedical Research Centre (BRC), Aziz Foundation, Wolfson Foundation, and the Royal College Surgeons of England. No funders had a direct role in this study. The views and opinions expressed are those of the authors and do not necessarily reflect those of the NIHR Academy, NIHR, Department of Veterans Affairs or the United States Government, NHS, or the Department of Health, England.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All the data partners received Institutional Review Board (IRB) approval or exemption. The research was approved by the Columbia University Institutional Review Board as an OHDSI network study. The use of SIDIAP was approved by the Clinical Research Ethics Committee of the IDIAPJGol (project code: 20/070-PCV. The use of the HealthVerity and Optum databases was reviewed by the New England Institutional Review Board (IRB) and were determined to be exempt from broad IRB approval. The use of IQVIA-OpenClaims and IQVIA LPD France were exempted from IRB approval. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yeshttps://data.ohdsi.org/Covid19CharacterizationCharybdis/ https://data.ohdsi.org/Covid19CharacterizationCharybdis/